Le Lézard
Classified in: Health, Science and technology

Global Genome Editing Markets, Competition, Forecast & Opportunities Report 2021-2026 - ResearchAndMarkets.com


The "Global Genome Editing Market, By Technique (CRISPR, TALENs, Zinc Finger Nucleases, Others), By Application (Cell Line Engineering, Animal Genetic Engineering, Others), By Delivery Method, By End User, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

The Global Genome Editing Market is expected to reach USD8711.24 million by 2026, growing at double-digit CAGR of 12.73%

Growing research & development activities for the treatment of various chronic diseases and increasing preference for personalized medicine are fueling the market growth of genome editing until 2026.

Genome editing is a way of making specific changes to the DNA of a cell or organism. It could be used to edit the genome of any organism. It uses a type of enzyme called an 'engineered nuclease' which cuts the genome in a specific place. After cutting the DNA in a specific place, the cell naturally repairs itself. It finds application in large number of areas, such as mutation, therapeutics, and agriculture biotechnology. Rise in the number of chronic and infectious diseases is likely to expand the scope of genome editing in the coming years.

The Global Genome Editing Market is segmented based on technique, application, delivery method, end-user, region and company. Based on technique, the market is segmented into CRISPR, TALENs, Zinc Finger Nucleases and others. CRISPR dominates the market in this segment and is expected to be the fastest growing segment because as it is cheaper and is the most efficient technique among the rest.

Based on application, the market is segmented into cell line engineering, animal genetic engineering, plant genetic engineering and others. Among them, the cell line engineering is expected to witness the highest growth rate in the coming years due to increase in the number of people suffering with genetic disorders and rising government funding for stem cell research.

Based on end-user, the Global Genome Editing Market is segmented into pharmaceutical & biotechnology companies, clinical research organization and research institutes. Pharmaceutical & biotechnology companies contribute to the largest share of revenue generation for the Global Genome Editing Market.

Growing establishment of biotech and pharma companies in emerging economies and growing usage of gene editing technique in research activities undertaken by them to manufacture and develop drugs for rare diseases are the enablers for the growth of the market.

The major players operating in the Global Genome Editing Market are

Report Scope:

Years considered for this report:

Global Genome Editing Market, By Technique:

Global Genome Editing Market, By Application:

Global Genome Editing Market, By Delivery Method:

Global Genome Editing Market, By End-User:

For more information about this report visit https://www.researchandmarkets.com/r/d2cjur


These press releases may also interest you

at 07:35
Ironwood Pharmaceuticals, Inc. , a GI-focused healthcare company, today announced positive, primary results up to Day 91 for its Phase II exploratory STARGAZE trial evaluating apraglutide in patients with steroid-refractory gastrointestinal acute...

at 07:35
dentalcorp Holdings Ltd. ("dentalcorp" or the "Company") , Canada's largest and one of North America's fastest growing networks of dental practices, today announced that it will present at the following investor conferences: 2024 Bloom Burton & Co....

at 07:30
Optimi Health Corp. (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly...

at 07:30
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of...

at 07:30
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024...

at 07:30
Ophthalmic lens technology leader HOYA Vision Care announced the launch of iD LifeStyle® 4 with 3D Binocular Visiontm technology, the newest progressive lens in its award-winning iD LifeStyle® family, now available to order across Canada. Building...



News published on and distributed by: